BioNTech ADRs rise on Phase 3 lung cancer data
BioNTech ADRs were up 3.7% to $110.34 as of midday Monday after the company said gotistobart nearly doubled median survival in a Phase 3 lung cancer trial.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.